Download PDF
CC BY 4.0 · Brazilian Journal of Oncology 2025; 21: s00451805098
DOI: 10.1055/s-0045-1805098
Case Report
Clinical Oncology

Crizotinib-Related Aseptic Abscesses in Lung Adenocarcinoma and ROS1-Gene Rearrangement: A Case Report

Thamires Oliveira-Silva 
1   Department of Clinical Oncology, Instituto D'OR de Pesquisa e Ensino, Rio de Janeiro, RJ, Brazil
,
Camila Naegele-Bazzanella 
1   Department of Clinical Oncology, Instituto D'OR de Pesquisa e Ensino, Rio de Janeiro, RJ, Brazil
,
Mauro Zukin 
1   Department of Clinical Oncology, Instituto D'OR de Pesquisa e Ensino, Rio de Janeiro, RJ, Brazil
,
Nicolle Cavalcante 
2   Department of Pathology, Instituto D'OR de Pesquisa e Ensino, Rio de Janeiro, RJ, Brazil
,
Antônio Alexandre de-Oliveira-Siciliano 
3   Department of Radiology, Instituto D'OR de Pesquisa e Ensino, Rio de Janeiro, RJ, Brazil
,
Jaime Araújo-Oliveira-Neto 
3   Department of Radiology, Instituto D'OR de Pesquisa e Ensino, Rio de Janeiro, RJ, Brazil
,
Clarissa Baldotto 
1   Department of Clinical Oncology, Instituto D'OR de Pesquisa e Ensino, Rio de Janeiro, RJ, Brazil
› Author Affiliations
Funding The authors declare that they did not receive funding from agencies in the public, private, or non-profit sectors to conduct the present study.
› Further Information
  Permissions and Reprints All articles of this category

Abstract

Crizotinib is a multi-tyrosine kinase inhibitor (mTKI) with efficacy in treating c-ROS oncogene 1-positive non-small cell lung cancer (NSCLC). The association between this TKI and the development of renal cysts is well established, although data on the formation of aseptic abscesses is scarce. We report a case of a patient with ROS1-positive NSCLC treated with crizotinib who developed multiple renal and extrarenal cysts and aseptic abscesses associated with a quick resolution of these lesions after the discontinuation of the TKI therapy. We aim to report a rare presentation of a drug-related adverse event with an unusual behavior.

Keywords

aseptic abscesses - crizotinib - lung cancer - ROS1 rearrangement - kidney cysts

Authors' Contributions

TOS: collection and assembly of data, conception and design, data analysis and interpretation, final approval of the manuscript, and writing of the manuscript; CNB: collection and assembly of data, final approval of the manuscript, writing of the manuscript, provision of study materials or patient; MZ: final approval of the manuscript, and writing of the manuscript; NC: final approval of the manuscript, and writing of the manuscript; AAOS: final approval of the manuscript, and writing of the manuscript; JAON: collection and assembly of data, final approval of the manuscript, and writing of the manuscript; CB: collection and assembly of data, conception and design, data analysis and interpretation, final approval of the manuscript, and writing of the manuscript


Clinical Trials

None.




Publication History

Received: 14 April 2024

Accepted: 16 December 2024

Article published online:
25 March 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil

Bibliographical Record
Thamires Oliveira-Silva, Camila Naegele-Bazzanella, Mauro Zukin, Nicolle Cavalcante, Antônio Alexandre de-Oliveira-Siciliano, Jaime Araújo-Oliveira-Neto, Clarissa Baldotto. Crizotinib-Related Aseptic Abscesses in Lung Adenocarcinoma and ROS1-Gene Rearrangement: A Case Report. Brazilian Journal of Oncology 2025; 21: s00451805098.
DOI: 10.1055/s-0045-1805098
 

  • References

  • 1 Shaw AT, Riely GJ, Bang YJ. et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol 2019; 30 (07) 1121-1126
    Search in Google Scholar
  • 2 Halpenny DF, McEvoy S, Li A. et al. Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer-Incidence, radiological features and clinical characteristics. Lung Cancer 2017; 106: 33-36
    Search in Google Scholar
  • 3 Schnell P, Bartlett CH, Solomon BJ. et al. Complex renal cysts associated with crizotinib treatment. Cancer Med 2015; 4 (06) 887-896
    Search in Google Scholar
  • 4 Weber D, Decker M, Schuster M, Folz S, Stürmer CJ, Lutz MP. Crizotinib: aseptic abscesses in multiple organs during treatment of EML4-ALK-positive NSCLC. J Cancer Res Clin Oncol 2021; 147 (12) 3769-3771
    Search in Google Scholar
  • 5 de Carvalho L, Shimada A, Neto MC. et al. Development of Aseptic Renal Abscess in a Patient with Non-Small-Cell Lung Cancer with ALK Translocation during Crizotinib Treatment. Adv Lung Cancer (Irvine) 2015; 4: 53-57
    Search in Google Scholar
  • 6 Wiest NE, Tzou KS, Olson MT. et al. Crizotinib-associated renal cyst development may be associated with prolonged progression-free survival in patients with ALK-positive non-small-cell lung cancer: Case report and review of the literature. Clin Case Rep 2021; 9 (06) e04278
    Search in Google Scholar